Article
ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
Oncology reports - 1 Mar 2011
De Castro Gilberto, Pasini Fatima Solange, Siqueira Sheila Aparecida Coelho, Ferraz Alberto Rossetti, Villar Rosangela Correa, Snitcovsky Igor Moysés Longo, Federico Miriam Hatsue Honda
Abstract excerpt
Adjuvant cisplatin-based chemoradiation improves survival in HNSCC patients presenting with risk features. ERCC1 (excision repair cross-complementation group 1) is associated with resistance to chemo- and radiation therapy and may have a prognostic value in HNSCC patients. Here we studied ERCC1 expression and the polymorphism T19007C as prognostic markers in these patients. This is a retrospective and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.